🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

16 recruiting trials

for Myelofibrosis Due to and Following Polycythemia Vera

Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773n/a1 site📍 Hong Kong The University of Hong Kong Research Platform Myelofibrosis and Anemia NCT06976918n/a1 site📍 Multiple Locations iOMEDICO AG Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) NCT06327100Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ruxolitinib, Tasquinimod Therapeutic RSK1 Targeting in Myeloid Malignancies NCT07379125Phase 11 site📍 St Louis Washington University School of Medicine · Tests: PMD-026 A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) NCT06343805Phase 121 sites📍 Palo Alto📍 Tampa📍 Kansas City Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli L… · Tests: LY5830966 Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib NCT06479135Phase 3215 sites📍 Birmingham📍 Gilbert📍 Phoenix Kartos Therapeutics, Inc. · Tests: Navtemadlin, Navtemadlin placebo, Ruxolitinib Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia NCT05320198Phase 1, Phase 235 sites📍 Gilbert📍 Duarte📍 Irvine Disc Medicine, Inc · Tests: DISC-0974 A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis NCT05714072Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Ruxolitinib, Abemaciclib MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) NCT07362225n/a2 sites📍 Chicago📍 New York MPN Research Foundation Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib NCT05280509Phase 1, Phase 219 sites📍 Birmingham📍 Canton📍 Cincinnati Telios Pharma, Inc. · Tests: TL-895, Ruxolitinib A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727Phase 3148 sites📍 Denver📍 New Haven📍 Fort Myers Novartis Pharmaceuticals · Tests: Pelabresib, Ruxolitinib, Placebo Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis NCT06517875Phase 233 sites📍 Ann Arbor📍 New York📍 Nashville GlaxoSmithKline · Tests: Momelotinib, Luspatercept A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631Phase 321 sites📍 Ann Arbor📍 Durham📍 Columbus Merck Sharp & Dohme LLC · Tests: Bomedemstat A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms NCT07469891Phase 118 sites📍 Los Angeles📍 Denver📍 Coral Springs Prelude Therapeutics Incorporated · Tests: PRT12396 A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis NCT06073847n/a3 sites📍 Seoul📍 Seoul📍 Seoul Bristol-Myers Squibb · Tests: Fedratinib Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition NCT06218628Phase 11 site📍 Philadelphia Fox Chase Cancer Center · Tests: Talazoparib, pacritinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy